Zura Bio Limited (NASDAQ:ZURA) Receives Average Rating of “Moderate Buy” from Brokerages

Zura Bio Limited (NASDAQ:ZURA) has earned a consensus recommendation of “Moderate Buy” from the seven analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $17.00.

ZURA has been the topic of several recent research reports. Wedbush lifted their target price on shares of Zura Bio from $15.00 to $22.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th. William Blair assumed coverage on shares of Zura Bio in a research report on Wednesday, July 8th. They issued an “outperform” rating for the company. Wall Street Zen upgraded shares of Zura Bio from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Guggenheim lifted their price objective on Zura Bio from $15.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a report on Monday, July 6th.

Zura Bio Price Performance

ZURA opened at $4.57 on Friday. Zura Bio has a fifty-two week low of $1.88 and a fifty-two week high of $7.44. The firm’s fifty day moving average price is $5.56 and its two-hundred day moving average price is $5.30. The company has a market capitalization of $437.94 million, a P/E ratio of -4.04 and a beta of -0.02.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Tuesday, June 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. On average, equities research analysts expect that Zura Bio will post -0.81 EPS for the current fiscal year.

Institutional Trading of Zura Bio

Large investors have recently bought and sold shares of the stock. Allworth Financial LP bought a new position in shares of Zura Bio during the fourth quarter valued at $30,000. Dimensional Fund Advisors LP grew its holdings in shares of Zura Bio by 83.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 43,135 shares of the company’s stock worth $257,000 after purchasing an additional 19,603 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Zura Bio by 3,007.7% in the 1st quarter. Bank of America Corp DE now owns 136,523 shares of the company’s stock worth $812,000 after purchasing an additional 132,130 shares during the last quarter. Seven Fleet Capital Management LP acquired a new stake in shares of Zura Bio during the 4th quarter worth about $872,000. Finally, 683 Capital Management LLC acquired a new position in Zura Bio in the fourth quarter valued at about $1,358,000. 61.14% of the stock is currently owned by institutional investors.

Zura Bio Company Profile

Zura Bio Limited (NASDAQ: ZURA) is a clinical-stage biotechnology company focused on developing medicines for chronic inflammatory and immune-mediated diseases. The company is advancing therapies designed to address conditions with significant unmet medical needs, including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and inflammatory bowel disease.

Zura Bio’s pipeline includes ZB-106, an investigational inhibitor of interleukin-17A and interleukin-17F being evaluated in inflammatory diseases, and ZB-880, an investigational therapy targeting TL1A, a cytokine associated with intestinal inflammation.